Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World
Pharmaceuticals · 21.09.2023 · 16 (9) · 1334
DOI: 10.3390/ph16091334 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 21.09.2023. Verfasst von Luis E Fernández-Garza und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio Nacional de Servicios Especializados de Investigación, Desarrollo e Innovación de Farmoquímicos y Biotecnológicos (LANSEIDI) del CONACyT,…. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cellular therapy has used mesenchymal stem cells (MSCs), which in cell culture are multipotent progenitors capable of producing a variety of cells limited to the mesoderm layer. There are two types of MSC sources: (1) adult MSCs, which are obtained from bone marrow, adipose tissue, peripheral blood, and dental pulp; and (2) neonatal-tissue-derived MSCs, obtained from extra-embryonic tissues such as the placenta, amnion, and umbilical cord. Until April 2023, 1120 registered clinical trials had been using MSC therapies worldwide, but there are only 12 MSC therapies that have been approved by regulatory agencies for commercialization. Nine of the twelve MSC-approved products are from Asia, with Republic of Korea being the country with the most approved therapies. In the future, MSCs will play an important role in the treatment of many diseases. However, there are many issues to deal with before their application and usage in the medical field. Some strategies have been proposed to face these problems with the hope of reaching the objective of applying these MSC therapies at optimal therapeutic levels.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratorio Nacional de Servicios Especializados de Investigación, Desarrollo e Innovación de Farmoquímicos y Biotecnológicos (LANSEIDI) del CONACyT, Sede Innbiogem SC, Monterrey 64630, Mexico.
- Departamento de Medicina Interna, Hospital General de Zona con Medicina Familiar No. 2 del Instituto Nacional del Seguro Social, Monterrey 64010, Mexico.
- Facultades de Medicina y Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66455, Mexico.
- Columbia Investigación Científica, Panzacola 62, Colonia Villa Coyoacán, Alcaldía Coyoacán, Ciudad de Mexico 04010, Mexico.
ORCID-Profile: Luis E Fernández-Garza
Zitieren
APA
Fernández-Garza, L. E., Barrera-Barrera, S. A., & Barrera-Saldaña, H. A. (2023). Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World. Pharmaceuticals, 16(9), 1334. https://doi.org/10.3390/ph16091334
Vancouver
Fernández-Garza LE, Barrera-Barrera SA, Barrera-Saldaña HA. Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World. Pharmaceuticals. 2023;16(9):1334. doi:10.3390/ph16091334
BibTeX
@article{FernndezGarza2023,
author = {Fernández-Garza, Luis E and Barrera-Barrera, Silvia A and Barrera-Saldaña, Hugo A},
title = {Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {9},
pages = {1334},
doi = {10.3390/ph16091334}
}
EUVIMED